Akero Therapeutics (AKRO) Competitors

Akero Therapeutics (NASDAQ:AKRO) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Do analysts prefer AKRO or GMAB?

Akero Therapeutics presently has a consensus target price of $82.33, indicating a potential upside of 73.08%. Genmab A/S has a consensus target price of $39.17, indicating a potential upside of 92.65%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Akero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Which has more risk & volatility, AKRO or GMAB?

Akero Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Does the MarketBeat Community favor AKRO or GMAB?

Genmab A/S received 49 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 65.56% of users gave Akero Therapeutics an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Akero Therapeutics	Outperform Votes 118 65.56%	Underperform Votes 62 34.44%
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%

Do institutionals & insiders hold more shares of AKRO or GMAB?

7.1% of Genmab A/S shares are owned by institutional investors. 7.9% of Akero Therapeutics shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media favor AKRO or GMAB?

In the previous week, Genmab A/S had 10 more articles in the media than Akero Therapeutics. MarketBeat recorded 24 mentions for Genmab A/S and 14 mentions for Akero Therapeutics. Genmab A/S's average media sentiment score of 0.70 beat Akero Therapeutics' score of 0.68 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akero Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	10 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is AKRO or GMAB more profitable?

Genmab A/S has a net margin of 36.30% compared to Akero Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 16.78% beat Akero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akero Therapeutics	N/A	-32.46%	-29.83%
Genmab A/S	36.30%	16.78%	13.79%

Which has higher valuation and earnings, AKRO or GMAB?

Genmab A/S has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akero Therapeutics	N/A	N/A	-$151.76M	-$1.95	-24.39
Genmab A/S	$3.12B	4.18	$1.14B	$1.76	11.55

Summary

Genmab A/S beats Akero Therapeutics on 14 of the 17 factors compared between the two stocks.